Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 9/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3225036 | 0.95 | PDCD1 (0.46) | PDCD1CD274HDAC1DRD2CSF1R | |
| SCHEMBL3229584 | 0.94 | PDCD1 (0.47) | PDCD1CD274ACKR3HDAC1DRD2 | |
| SCHEMBL1496840 | 0.92 | ACKR3 (0.44) | PDCD1CD274ACKR3HDAC1FGFR1 | |
| SCHEMBL12249896 | 0.91 | HTT (0.46) | PDCD1CD274HDAC1KMT2A | |
| SCHEMBL13585490 | 0.91 | PDCD1 (0.45) | PDCD1CD274ACKR3HDAC1FGFR1 | |
| SCHEMBL3224383 | 0.91 | PDCD1 (0.46) | PDCD1CD274HDAC1DRD2 | |
| SCHEMBL3232563 | 0.91 | PDCD1 (0.50) | PDCD1CD274ACKR3HDAC1DRD2 | |
| SCHEMBL3230045 | 0.89 | CD274 (0.45) | PDCD1CD274HDAC1KMT2A | |
| SCHEMBL3230240 | 0.88 | CD274 (0.44) | PDCD1CD274HDAC1DRD2 | |
| SCHEMBL2473832 | 0.87 | HDAC1 (0.52) | CD274ACKR3HDAC1DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012972-B2 | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2133339-A1 | NOVEL (2-AMINOPHENYL)PYRIDINECARBOXAMIDE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063045-A1 | NOVEL PYRIDINECARBOXYLIC ACID (2-AMINOPHENYL) AMIDE DERIVATIVE HAVING UREA STRUCTURE | HCAR1, CBR1, UACA | PDCD1 1397/4885CD274 2587/4885ACKR3 275/4885 |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | PDCD1 4109/4885CD274 4707/4885ACKR3 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.